| Q41199022 | Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study |
| Q54363389 | Activity of the pyrazoloacridines against multidrug-resistant tumor cells. |
| Q71971829 | An Effective Salvage Regimen with Aclarubicin for Daunorubicin-Resistant Acute Non-Lymphocytic Leukemia in Children |
| Q54268568 | Intensive sequential post-induction therapy for adults with acute myelogenous leukemia in first remission: Long-term follow-up and results |
| Q44133296 | Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy |
| Q33479596 | Phase II trial of aclacinomycin A in acute leukemia and various solid tumors |
| Q54437332 | Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma. |
| Q45076097 | Refractory acute lymphocytic leukemia: response to aclacinomycin A and VP-16-213. |
| Q37188707 | TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma |
| Q35992543 | The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach |
| Q40108900 | Treatment of Acute Leukemia–Advances in Chemotherapy, Immunotherapy, and Bone Marrow Transplantation |
| Q37909059 | Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment |